OSI maintained at buy by Merrill

OSI Pharmaceuticals, Inc. was kept at a buy by Merrill Lynch analyst Eric Ende on news that Tarceva sales of $103 million were modestly ahead of the analyst's and consensus estimates of $101 million. Merrill raised its earnings-per-share estimate for the second quarter by 2 cents. Shares of the Melville, N.Y.-based pharmaceutical company were up $1.87, or 6.14%, at $32.31 on volume of 2,636,298 shares versus the three-month running average of 1,219,020 shares. (Nasdaq: OSIP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.